Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
|Articles|July 31, 2020
- Pharmaceutical Technology's In the Lab eNewsletter 08-05-2020
- Volume 15
- Issue 8
Primera Technology Introduces Signature Slide and Cassette Printers
The printers can print text, graphics, logos, and 2D bar codes directly onto slides and cassette.
Advertisement
Primera Technology introduced its Signature Slide and Cassette Printers with integrated PTLab software for increasing lab efficiency and reducing the risk of specimen misidentification.
According to a July 13, 2020 press release, the printers can print text, graphics, logos, and 2D bar codes directly onto slides and cassette. The devices also include:
- On-demand, black or color printing
- Small footprints
- Reduced inventories and purchasing activity
- Thermal-transfer printing at high-resolution, 300 dpi
- On-demand or batch mode printing
Source:
Articles in this issue
about 6 years ago
Using Analytical Assays to Ensure Biosimilar Qualityabout 6 years ago
A Novel Method for Host Cell Protein Analysisabout 6 years ago
MilliporeSigma Invests $20 Million in New Switzerland Laboratoryabout 6 years ago
MOBILIon’s SLIM Technology Enhances R&D Analyticsabout 6 years ago
LabVantage Adds an SDMS to the 8.5 Edition of its LIMS PlatformAdvertisement
Related to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
3
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
4
Nitrosamine Problems and Industry Solutions: PharmTech Explained
5